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Objective: To systematically review the use of Quantitative sensory testing (QST) in pain characterisation
(phenotyping) in Osteoarthritis (OA).
Methods: Six bibliographic databases (Medline, Embase, Amed, Cinahl, PubMed, Web of Science) were
searched to identify studies published before May 2011. Data were extracted based on the primary site of
OA, QST modalities, outcome measures and test sites. Standardised mean difference (SMD) and 95%
conﬁdence intervals (CIs) were calculated if possible. Publication bias was determined using funnel plot
and Egger’s test. Heterogeneity was examined using Cochran Q test and I2 statistic. Random effects model
was used to pool the results.
Results: Of 41 studies (2281 participants) included, 23 were case control studies, 15 case only studies, two
randomised controlled trials, and one uncontrolled trial. The majority of studies examined pressure pain
with smaller numbers using electrical and/or thermal stimuli. QST was more often applied to the affected
joint than distal and remote sites. Of 20 studies comparing people with OA and healthy controls, seven
provided sufﬁcient information for meta-analysis. Compared with controls, people with OA had lower
pressure pain thresholds (PPTs) both at the affected joint (SMD¼1.24, 95%CI 1.54, 0.93) and at
remote sites (SMD¼0.88, 95%CI 1.11, 0.65).
Conclusion: QST of PPTs demonstrated good ability to differentiate between people with OA and healthy
controls. Lower PPTs in people with OA in affected sites may suggest peripheral, and in remote sites
central, sensitisation. PPT measurement merits further evaluation as a tool for phenotyping OA pain.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most common form of arthritis and
a major cause of chronic musculoskeletal pain and disability,
worldwide1. Although joint damage and inﬂammation are widely
recognised as major contributing factors, the pathophysiology of
OA pain remains relatively poorly understood2. Multiple mecha-
nisms ranging from local to neurogenic3,4 can contribute to OA pain
severity, and factors extrinsic to the joint, such as periarticular and
central sensitisation5e7, may be important in the maintenance of
pain. Sensitisation, in turn, may trigger a transition from acute to.K. Suokas, Arthritis Research
ences Building, City Hospital,
5-823-1092; Fax: 44-(0)-115-
. Suokas).
s Research Society International. Pchronic pain and inﬂuence responses to treatment. Studies suggest,
for example, that radiographic evidence does not always match the
individual’s report of pain8e10 and 10e20% of people with knee OA
still have persistent severe knee pain after total knee
replacement11e13. The complexity of OA pain means that treat-
ments targeting one speciﬁc mechanism may have low efﬁcacy if
offered to people whose pain is largely mediated by other mecha-
nisms. Treatment guidelines therefore recommend that the optimal
management of OA should be tailored according to patient char-
acteristics including pain phenotyping14,15.
Quantitative sensory testing (QST) is one approach that has been
used to evaluate mechanism- (as opposed to symptoms-) based
phenotyping of OA pain. QST involves assessing somatosensory
evoked responses to noxious or innocuous stimuli using controlled
mechanical, chemical, electrical, and/or thermal test modalities16.
The examiner systematically applies a stimulus to an anatomical test
site (e.g., joint,muscle or tendon)until thestudyparticipant indicatesublished by Elsevier Ltd. All rights reserved.
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assessed at the affected anatomical site to identify localised, or at
a distal or remote site to identify regional or widespread, somato-
sensory changes17. Localised pain on the affected joint is associated
with peripheral sensitisation, whereas pain at a site adjacent to or at
adistance fromthesiteof origin suggests a combinationofperipheral
and central sensitisation18. In QST,methods have been developed for
investigating complex pain mechanisms such as peripheral and
central sensitisation, descending pain control, and referred pain19.
QST has also been used to explore differences between diseased and
control populations12,20e26, to investigate pain mecha-
nisms7,22,24,27e29,30,31, and to predict32e34 or measure responses to
interventions24,28,35e37. However, published studies have provided
variable results, leading to uncertainty as to the extent that pain
thresholds and sensory detection thresholds in people with OA may
differ from those in healthy people.
The aims of this systematic review and meta-analysis were to
examine: [1] the use of QST in OA (modalities, outcome measures
and anatomical test sites); [2] the reliability of QST; [3] the ability of
QST to differentiate people with OA from healthy controls, and [4]
differences between anatomical test sites.
Methods
Systematic literature search
Six bibliographic databases (Medline 1948-, Embase 1980-,
Amed 1985-, Cinahl 1981-, PubMed 1950- and Web of Science
1970-) were searched to identify studies published in peer-
reviewed journals before May 2011. A systematic search strategy
was developed in Medline (see Appendix 1) and replicated as
closely as possible in the other bibliographic databases. Additional
studies were identiﬁed by searching the references of the included
articles. Reports were downloaded into Endnote X4.
Inclusion/exclusion criteria
Primary studies of any type of research design involving people
with OA were eligible when they: 1) applied at least one of the
following QST modalities: chemical, electrical, mechanical or
thermal stimulus; 2) measured perception of noxious or innocuous
stimuli applied to skin, muscle or joint; 3) used a testing protocol to
control for stimulus properties: modality, anatomical site, intensity,
duration, and sequence; 4) reported the ﬁndings in a peer-reviewed
academic journal. Each abstract was assessed by AS for potential
relevance. Full text was retrieved for articles that appeared relevant
for further analysis. There was no language restriction.
Full papers that met our criteria were included. A meta-analysis
comparing people with OA and healthy controls was undertaken if
possible. Additional data were obtained from the authors, if they
were not reported fully in the papers7,38,39.
Data-extraction
Standard informationwas extracted fromall eligible studies using
a single form suitable for all study designs. The information included
the following: study design, setting; sample selection; affected joint;
diagnostic criteria, demographic data; ethnicity; weight; body mass
index (BMI); pain severity on visual analogue scale (VAS) prior to
QST; stimulus protocol; QST modalities and outcome measures; the
anatomical site ofQST; and themeanvalues andestimates of random
variability of pain and/or sensory detection threshold measurement
using QST. The studies were classiﬁed into randomised controlled
trials (RCTs) and observational studies (cohort, case control, case
only). Setting was deﬁned as hospital or community settingaccording to the source of the population, or the source of the control
population if it was a case control study. English language data were
extracted and coded by one reviewer (AS), and a sub-set of key
variables was validated by four co-investigators (BM, DAW, DMcW
andLC).Discrepancies anddisagreementswere resolvedbyaﬁfth co-
investigator (WZ). Data-extraction in other languages required help
from native speakers with knowledge of rheumatology or neuro-
imaging research (see acknowledgements).
Quality and content assessment
Quality of the studies included in the meta-analysis was
examined using amodiﬁed version of the criteria devised by Downs
and Black40, which is generic to both RCTs and observational
studies. Each criterion was scored as 1 if present and 0 if absent or
unclear, and the maximum score was 12 (Appendix 2).
Data analysis
QST modalities, outcome measures and test sites
Data were categorised according to study design, setting, and
QST modalities including 1) electrical, 2) chemical, 3) mechanical
(sub-groups included pressure, punctate/brush, and vibratory) and
4) thermal stimulus. Anatomical QST sites were coded according to
their location in relation to the joint(s) reported as affected by OA in
each study, and organised into four categories: affected joint, distal,
remote, and other sites. Sites coded as ‘affected joint’ were on, or in
close proximity to, the primary site of OA in each study. ‘Distal’ sites
were below the affected joint and ‘remote’ sites above or contra-
lateral to the affected joint. For studies that did not distinguish
between uni- and bilateral OA, a contralateral site was coded as
‘remote’ if it was described as pain free. Sites were coded as ‘other’
if the study measured an average reading from two symmetrical
sites (e.g., both hands) or an average reading across affected, distal
and remote sites, or if the location was unclear. The data were
coded by one reviewer (AS) and validated by four co-investigators
(BM, DAW, DMcW, LC).
Reliability of QST, and the ability to differentiate between groups
Each study was screened for intraclass correlation coefﬁcients
(ICCs) describing the testeretest repeatability of QST. The reliability
of the measurement across test occasions was rated excellent if the
ICC> 0.75, adequate if 0.40e0.74, and poor if <0.4041. The ability of
QST to detect somatosensory differences between people with OA
and healthy controls was assessed using standardised mean
differences (SMDs). SMD was calculated to estimate the magnitude
of the difference (Cohen’s d) between people with OA and healthy
controls. By convention, a SMD or d¼ 0.2 is considered to be small,
d¼ 0.5moderate and d¼ 0.8 large in size42. This analysis could only
be performed for one outcome measure, pressure pain thresholds
(PPTs), due to the small number of case control studies spread
across many QST modalities (see Table I). PPTs were extracted in
and, where necessary, converted to kg/cm2. The SMDs and 95%
conﬁdence intervals (CIs) were presented using a forest plot.
Publication bias was examined using a funnel plot and an Egger’s
test. The Q test and I2 statistics were calculated to measure the
degree of heterogeneity between studies. The Q test suggests
a signiﬁcant level of heterogeneity if statistically signiﬁcant
(P< 0.05) whereas the I2 value (0e100%) indicates a percentage of
the heterogeneity across studies that is not due to chance43,44.
QST results from different anatomical test sites
QST results from different anatomical test sites were assessed by
examining forest plots for SMDs using the methods described
above. Statistical pooling was undertaken as appropriate according
Table I
Study characteristics
Case control Case only Other* All studies
No. studies 23 15 3 41
No. subjects 1265 859 157 2281
Mean age 60 64 60 62
Female % 64 64 45 62
Setting
Hospital 7 6 2 15
Community 4 3 0 7
Not known 12 6 1 19
Affected joint
Knee 14 13 1 28
Hip 5 0 0 5
Hand 1 1 0 2
Multiple/not speciﬁed 3 1 2 6
QST modalityy
Mechanical 18 8 2 28
Pressure 13 6 2 21
Punctate, brush 6 2 0 8
Vibratory 2 0 0 2
Electrical 4 6 1 11
Thermal 7 4 0 11
Chemical 2 0 0 2
Outcome measurey
Pain threshold 17 12 1 30
Detection threshold 9 1 0 10
Pain intensity 4 3 2 9
Muscle reﬂex 2 2 0 4
Brain activity 2 1 0 3
Otherz 3 1 0 4
QST test sitesy
Affected joint 11 8 2 21
Distal to affected joint 8 0 0 8
Remote from affected joint 9 4 0 13
Otherx 6 5 1 12
Affected joint¼main location of OA.
* Randomised control trial, uncontrolled trial.
y One study may involve more than one QST modality, outcome measure and test
site.
z Pain area, duration, tolerance.
x Average threshold reading from a number of anatomical test sites, or the
affected joint or anatomical test site not speciﬁed and thus not categorised.
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one anatomical site, the site with the smallest SMD was selected
when calculating the pooled SMD.
Other analyses
The minimum sample size needed to assure adequate statistical
power to detect differences between the two groups was investi-
gated for PPTs. This was calculated for affected, distal and remote
sites, and the minimum SMD for each site was selected to estimate
the minimum sample size required.We applied 90% power and less
than 5% Type I error for each calculation.
Analyses were performed using StatsDirect 2.7.8. and Power and
Sample Size Calculations 3.0.43.
Results
Characteristics of the included studies
Of 41 studies which met the inclusion criteria, 23 were case
control studies,15 case only studies, twoRCTs, and one uncontrolled
trial (Appendix 3). A ﬂow diagram in Fig. 1 presents the study
selection process, and the characteristics of the selected studies are
summarised in Table I. The total number of participants was 1265 in
case control studies, 859 in case only studies, and 157 in the other
designs. The mean age of participants in the studies was 62 years;women (62%) were more often seen than men. Of the 22 studies
which reported study setting, approximately one-third (7/22) were
community-based. While two-thirds (28/41) of the studies focused
on people with knee OA, the rest were undertaken in OA of other
joints, including hip (5/41), hand (2/41) or multiple joints (6/41).
Seven PPT studies speciﬁed a single area for the affected joint
(knee, hip, or hand) which allowed categorisation of the anatomical
QST test sites (affected joint, distal, remote, other), and only this
group of seven studies was included in the meta-analysis. The
quality scores for the seven studies included in the meta-analysis
varied between 8 and 10 (maximum 12). The criteria frequently
not met were reporting of source population especially for healthy
controls; random selection of cases; and power and sample size
calculations.
QST modalities, outcome measures and test sites
Individual studies could involve more than one QST modality,
outcome measure and anatomical test site (i.e., the total for each
item may exceed 41). The majority (30/41) of the studies admin-
istered mechanical stimulus, and the most commonly used
method was pressure which was applied in 21 studies (Table I).
The next most common modalities were electrical (11/41) and
thermal (11/41) and a small number of studies (2/41) applied
chemical stimulus.
The studies were primarily concerned with pain thresholds (30/
41) and other common outcome measures included detection, i.e.,
ﬁrst sensation thresholds (10/41) and intensity of painmeasured on
a scale (9/41). Small numbers of studies (four and three, respec-
tively, of 41) examined muscle reﬂexes using electromyographic
(EMG) recording, and brain activity during QST using functional
Magnetic Resonance Imaging (fMRI) or Positron Emission Tomog-
raphy (PET) scanning.
The studies typically involved QST of more than one anatomical
site, and the largest number of sites included in a single study was
2422. Coding of the anatomical sites demonstrated that 21 of the 41
studies applied stimuli to the primary site affected by OA, and that
13 studies tested remote and eight studies distal sites. Twelve
studies measured the average threshold from two or more sites
including the affected joint. Overall, differences in study protocols
resulted in heterogeneity which limited the comparison of study
results even within a single modality.
Reliability of QST
Three papers20,21,37 reported ICCs for the testeretest reliability
of QST in OA. In a knee OA study by Moss et al.37 the time between
PPT measurements was at least 48 h and the ICCs were near perfect
with an ICC of 0.98 (95%CI 0.96, 0.99) for both the affected knee and
the distal ipsilateral heel. Wessel20 tested PPTs in knee OA on six
sites on or above the knee in both legs. Measurements were taken
5e10 days apart and the ICCs varied from adequate (0.58) to
excellent (0.91). The most comprehensive analysis of ICCs was
carried out in a knee OA study byWylde et al.21 which involved two
types of mechanical (light touch, pressure pain) and three types of
thermal stimuli (cold, warm, hot pain). PPTs were found to be the
least variable measurement over a 1-week period, and the ICCs
were excellent for the affected knee (0.83, 95%CI 0.72, 0.90) and the
contralateral knee (0.77, 95%CI 0.63, 0.86) and the forearm (0.86,
95%CI 0.77, 0.92).
Ability of QST to differentiate between groups
Of 41 studies included, 13 reported that people with OA were
more sensitive than normal controls to painful stimuli
Fig. 1. Flow diagram of study selection.
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thermal pain threshold46, punctate pain threshold29,47, or chemical
pain rating27). Two further studies28,48 applying noxious electro-
cutaneous stimuli reported that the threshold to elicit ﬂexor
withdrawal reﬂex was signiﬁcantly lower in the OA group. Three
studies reported no signiﬁcant difference between the OA and the
normal control groups (‘piston’ pressure pain ratings31, ﬁnger
pressure pain ratings49, heat and cold pain47). In contrast to pain
studies, sensory detection thresholds in people with OA were
reported to be either higher, i.e., indicative of hypoesthesia
(vibratory50,51, innocuous punctate29), or similar to those of healthy
controls (electrical46, light touch and innocuous cold24, warm and
cool47).
Sufﬁcient data were available from seven studies to undertake
meta-analysis comparing PPTs between people with OA and
healthy controls. The mean (standard deviation (SD)) of the PPT in
kg/cm2 for different anatomical test sites among the included
studies varied from 1.81 (1.00) to 5.22 (2.26) in people with OA, and
from 3.40 (0.84) to 11.20 (2.03) in healthy controls. SMDs between
the groups ranged from 0.47 (95%CI 1.00, 0.06) to 3.04 (95%CI
3.77, 2.31) (Fig. 2), where the negative value means lower pain
threshold in OA. All but one site in one study7 demonstrated
a signiﬁcant lower PPT in OA. The one study52 that reported that
PPTs were higher in people with OA than healthy controls was not
included in the meta-analysis because the affected joint was not
speciﬁed and therefore the anatomical test sites could not be cat-
egorised in relation to the affected joint.The pooled SMD, calculated by selecting the anatomical QST site
with the smallest SMD from each study, was 0.87 (95%CI 1.08,
0.66) (Fig. 3). Funnel plot and Egger’s test (bias¼0.70, P¼ 0.69)
from the seven studies did not suggest signiﬁcant publication bias
(Fig. 4), and the Q test (Q¼ 6.34, P¼ 0.39) and the I2 test (5%, 95%CI
0%, 61%) did not indicate heterogeneity between studies (Fig. 3).
QST results from different anatomical test sites
For most studies, PPTs were reported to be reduced in people
with OA compared with controls, irrespective of whether tested at
affected, distal or remote sites. This is exempliﬁed by Imamura
et al.22 who reported signiﬁcantly lower PPTs in people with knee
OA when applying stimuli to skin overlying muscle or bone at all
18 anatomical test sites including upper thigh and lower back.
Similarly, Lee et al.23 reported lower thresholds for thumb,
shoulder and front of the thigh, and Wylde et al.38 for forearm, in
people with knee OA. However, one study52 reported that PPTs
were higher in people with OA than normal healthy controls and
another24 reported that PPTs for people with hip OA on sites
contralateral to the affected site were similar to those of normal
healthy controls.
The smallest SMD for the affected joint, distal and the remote
anatomical test sites were selected from each study and pooled
within these three categories (Fig. 5). The SMD was larger for the
affected joint sites (SMD¼1.24, 95%CI 1.54, 0.93) compared
with remote sites (SMD¼0.88, 95%CI 1.11, 0.65). The
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(1.22) compared to 3.40 (0.84) in the control group for the affected
sites, whereas it was 2.27 (1.52) vs 3.45 (1.00) for the remote sites.
For distal sites, which involved only three anatomical sites from
two studies, there was no signiﬁcant difference between the OA
and the control group.AFFECTED
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Fig. 2. Forest plot showing the SMD (95%CIs) for PPT between people with OA and healthy co
other). L1eL5¼ lumbar vertebrae, S1eS2¼ sacral vertebrae, MCP¼metacarpophalangeal. O
lower pain threshold in OA compared with control.Other analyses
The minimum sample size needed to assure adequate statistical
power to detect differences between the two groups was investi-
gated for PPTs. For the affected joint the minimum SMD was 0.68
(mean difference1.78 kg/cm2, SD 2.57). The sample size needed to-0.84 (-1.39, -0.29)
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Fig. 5. Forest plot showing the pooled SMD (95%CIs, n¼ number of studies,
pts¼ number of study participants) for PPT between people with OA and healthy
controls. The smallest SMD for the affected joint, distal site, and the remote site were
selected from each study and pooled within these three categories. Negative SMD
means lower pain threshold in OA compared with control.
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Fig. 3. Forest plot showing the SMD (95%CIs) for PPT between people with OA and
healthy controls. The anatomical test sitewith the smallest SMDwas selected from each
study. Test for heterogeneity: Cochran Q¼ 6.34, P¼ 0.39, I2 (inconsistency)¼ 5% (95%
CI¼ 0e61%). Negative SMD means lower pain threshold in OA compared with control.
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would be 45 people per group to give a power of 90% and false
positive error of less than 5% (Fig. 6). The minimum SMD for sites
distal to the affected jointwas0.47 (mean difference0.98 kg/cm2,
SD 2.03), and the sample size needed to detect this difference would
be91pergroup.Forsites remote fromtheaffected joint theminimum
SMDwas0.74 (meandifference0.73kg/cm2, SD0.97)25,26, and the
sample size required to detect this differencewould be 39 per group.
Finally, for a study which aims to test all three sites (affected, distal
andremote) theminimumsample sizewouldbe91peoplepergroup.Discussion
Application and reliability of QST as a research method
Pressure stimulus emerged as the most common method for
assessing somatosensory responses and for showing abnormalities
in the target population, and QST was more often applied to the
affected joint than distal and remote sites. The magnitude of
difference (SMD) in PPTs was large, and the minimum number
required to differentiate people with OA and healthy controls using
QST at a single site was 45 per group to ensure 90% power and less
than 5% false positive error. High testeretest repeatability indicates
that PPTs behave as stable characteristics over periods at least up to
1 week, and that pressure stimulus provides a reliable tool for
measuring pain thresholds.Affectedjoint
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Fig. 4. Funnel plot for PPT studies (n¼ 7) comparing people with OA and healthy
controls. The anatomical test site with the smallest SMD was selected from each study
and categorised into affected joint, distal site, remote site, or other. Test for publication
bias: Egger’s test¼0.70 (95%CI¼4.88 to 3.48), P¼ 0.69.Ability of QST to differentiate between groups
The ﬁndings from this review indicate that pain threshold may
be lower in people with OA than healthy controls. However, the
results from the included studies are variable and sometimes
contradictory. While some studies showed that people with OA
may have lower pain7,20,22e26,28,38,48 and higher sensory detec-
tion29,50,51,53 thresholds, others found that pain31,47,49 and sensory
detection24,46,47 thresholds in people with OAwere similar to those
of healthy controls. PPTsmeasured over or remote from the affected
joint displayed similar abilities to differentiate between groups.
Anatomical sites of QST and evidence of sensitisation
The key ﬁnding from the meta-analysis was that compared with
healthy controls, people with OA had lower PPTs not only in the
affected joint but also at remote sites not directly affected by OA
(spreading sensitisation). Investigating the locations and patterns
of pain e such as categorising knee OA pain as localised, regional or
diffuse54 e holds promise for better understanding sensory
abnormalities. Low PPTs over the affected joint may represent
nociception, for example due to local inﬂammation, while reduced
pain thresholds at sites remote from the affected joint support the
hypothesis that central sensitisation or reduced descending
inhibitory control may be important mediators of chronic muscu-
loskeletal pain16. Pain experienced distal to the site of pathology is
described as ‘referred pain’, and increased brain activation during
stimulation of sites corresponding to referred pain areas has been
associated with neuropathic-like pain symptoms, and is further0
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Fig. 6. Sample size and power calculation based on the minimum SMD.
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pain thresholds and brain function, as determined by fMRI55, and
normalisation24 after surgical interventions that reduce nociceptive
input further support the hypothesis that QST results reﬂect alter-
ations in central pain processing.
Central sensitisation both may be a consequence of ongoing
nociceptive input and a mechanism by which OA pain is main-
tained. Normalisation of PPTs following knee replacement sur-
gery24e26 indicates that treatments directed at the joint may reduce
sensitisation, whereas poor surgical outcomes in people with QST
evidence of preoperative central sensitisation56 suggests persistent
pain processing abnormalities. Further prospective studies would
be required to determine whether evidence of somatosensory
abnormalities could be used clinically to predict persistent post-
operative pain, or to help target adjunctive therapies in order to
improve pain outcomes after surgery, as recently was suggested for
the centrally acting analgesic pregabalin5.
Methodological issues
Bearing in mind the diversity of QST protocols we observed
across studies, in future research it may be necessary to improve
the reproducibility and comparability of studies. The adoption of
standardised QST protocols (e.g., the German Research Network on
Neuropathic Pain57) in OA studies would facilitate comparisons
between studies and groups, and pooling of data would permit
greater conﬁdence in the generalisability of study results. Gen-
eralisability can also be improved by appropriate sample size and
power calculation.
Further, methodological quality could be improved by experi-
mental designs that link up with theories of somatosensory pro-
cessing. Identiﬁcation of the locations and patterns of pain, and
exploring the relationship between pain patterns and OA risk
factors54, will provide valuable information about the aetiology and
nature of sensory abnormalities. Using QST alongside other clinical
studymethods (e.g., imaging evidence)maybe particularly useful in
studying the complex mechanisms of peripheral and central sensi-
tisation. Methods have been developed to enable comparison of
individual patients with OA to the group average of healthy partic-
ipants38,57, thus complementing the current practice of comparing
somatosensory abnormalities at group level. Finally, large RCTs are
required to assess the ability of QST tophenotype individual patients
in order to direct therapy and improve treatment outcomes.
Caveats of the study
A number of caveats need to be noted in this systematic review.
Firstly, the screening and selection of studies were carried out by only
one assessor, whichmeans that some relevant studiesmay have been
excluded from the review. Secondly, quality assessment was only
carried out for the studies included in themeta-analysis, and the brief
narrative review of ﬁndings was not interpreted in context with the
methodologicalqualityof the studies. Thirdly, it ispossible thatOAwas
present in joints that were not examined and reported in the studies,
which would affect the precision of our analysis. Fourthly, the small
number of studies for each QST modality and the heterogeneity of
stimulus protocols made the comparison of results difﬁcult. Differ-
ences in absolute values of thresholds between studies may result
from different stimulus protocols, but our ﬁndings indicate that
reductions in PPTs in people with OA can be demonstrated across
a range of study populations using differentmethodologies. However,
it is worth noting that small study effects may distort results of meta-
analyses as small studies tend to report larger effect sizes than larger
studies58. Finally, the sevenstudies included inthemeta-analysiswere
case control studies, and the difference in QST results between the OAand the control groups may be confounded by factors such as age,
gender, co-morbidities, andother painful joints and conditions. Due to
insufﬁcient reportingofdatawewereunable toadjust forconfounding
factors that couldhave resulted in limited comparabilityof the studies.
Conclusion
Current evidence conﬁrms that people with OA have lower PPTs.
This can be detected at both affected and unaffected sites, sug-
gesting that central sensitisation contributes to pain in OA. QST
merits further investigation as a research tool to help understand
pain mechanism in OA. More research is also needed to realise the
potential of QST to deﬁne pain phenotypes that could help target
speciﬁc treatments to those who are most likely to beneﬁt.
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Appendix 1. MEDLINE search strategy
1. osteoarthritis.mp. or exp Osteoarthritis, Hip/ or exp Osteoar-
thritis/ or exp Osteoarthritis, Spine/ or exp Osteoarthritis, Knee/
2. osteoarthrosis.mp.
3. gonarthritis.mp.
4. gonarthrosis.mp.
5. gonitis.mp.
6. coxarthritis.mp.
7. coxarthrosis.mp.
8. coxitis.mp.
9. knee pain.mp.
10. exp Osteophyte/ or osteophyte*.mp.
11. (joint space adj6 narrow*).tw.
12. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13. quantitative sensory.mp.
14. exp Sensory Thresholds/
15. exp Pain Threshold/
16. threshold*.mp.
17. 13 or 14 or 15 or 16
18. 12 and 17
A.K. Suokas et al. / Osteoarthritis and Cartilage 20 (2012) 1075e10851082Appendix 2. Checklist for study qualityScoring: yes¼ 1 no¼ 0; unless stated otherwise Yes No
Reporting
1. Does the study provide a clear a hypothesis/aim/objective for measurement of pain/sensory/reﬂex thresholds using QST*: to
detect differences in thresholds e why, for what purpose.
2. Are the main outcomes to be measured clearly described in the Introduction or Methods section (and not just in the Results):
thresholds and ratings.
3. Are the characteristics of the patients included in the study clearly described:
 cohorts and trials:
B inclusion criteria yes¼ 0.5;
B exclusion criteria yes¼ 0.5.
 case control studies:
B case-deﬁnition yes¼ 0.5;
B source for controls yes¼ 0.5.
 case only studies: case-deﬁnition yes¼ 1.
4. Are the distributions of principal confounders in each group of subjects to be compared clearly described: patient demographics
for age and gender either in a table or in text.
5. Are the main ﬁndings of the study clearly described by providing simple outcome data: numeric values (e.g., mean value) so that
reader can check the major analyses and conclusions.
6. Does the study provide estimates of the random variability in the data for the main outcomes: SE, SD, or CIs for parametric data;
inter-quartile range for non-parametric.
7. Have actual probability values been reported for the main outcomes (e.g., 0.035 rather than <0.05) except where P< 0.001.
Validity
8. If any of the results were based on ‘data dredging’, was this made clear (if no data dredging reported then answer yes).
9. Were the statistical tests used to assess the main outcomes appropriate: to detect differences in thresholds between time-points,
groups, interventions etc.
10.Were the cases representative of the entire population from which they were recruited: unselected sample of consecutive
patients or a random sample.
11.Were power calculations carried out for the primary outcome: threshold measurement.
12.Was there adequate adjustment for confounding in the analyses from which the main ﬁndings were drawn: were the groups age
and gender matched e if not, was this caveat discussed.
Total
* QST deﬁned as inclusion of one or several of the following modalities: mechanical (e.g., pressure, punctate, and light touch), thermal, electrical, chemical.mean Female% Affected QST QST Distal Remote Other*Appendix 3. Individual study characteristics
Author & year Country Design Setting Participants Age
(SD/range) joint modalities affected
Arendt-Nielsen et al. (2010)7 Denmark cc Unknown 72 62 (8) 50 Knee C, M Y Y Y
Bajaj et al. (2001)27 Denmark cc Unknown 28 40 (12) 57 Hip and
below
C Y
Brucini et al. (1981)59 Italy cc Unknown 26 (24e76) 50 Knee E Y
Bufﬁngton et al. (2005)49 USA cc Comm 16 48 (13/32e76) 44 Knee M Y
Courtney et al. (2009)48 USA cc Comm 40 61 (9/45e75) 60 Knee E Y
Courtney et al. (2010)28 USA cc Hosp 20 60 (45e75) 60 Knee E Y
Creamer et al. (1998)60 USA co Hosp 58 66 (10) 69 Knee M Y
Creamer et al. (1999)61 USA co Hosp 68 66 (10/40e86) 69 Knee M Y
Creamer et al. (1999)62 USA co Unknown 37 65 (9) 59 Knee M Y
Defrin et al. (2005)63 Israel co Hosp 62 69 (9/55e75) Knee E Y
Dragani et al. (1992)64 Italy co Unknown 20 62 (55e72) 100 Knee E Y
Emery et al. (2006)65 USA co Unknown 62 63 (8/50e76) 56 Knee E Y
Farrell et al. (2000)45 Australia cc Unknown 80 65 (8) 79 Hand M, T Y
Farrell et al. (2000)66 Australia co Unknown 24 64 (7) 100 Hand E, M, T Y
France et al. (2004)67 USA co Comm 132 63 (8) 56 Knee E Y
Gelecek et al. (2006)68 Turkey co Unknown 63 55 (11/40e65) 67 Hip/knee/
shoulder
M Y Y
Gerecz-Simon et al. (1989)52 Canada cc Unknown 72 48 (20e70) 50 Hip/knee M Y Y
Gwilym et al. (2009)47 UK cc Hosp 24 64 (9) 46 Hip M, T Y
Hendiani et al. (2003)29 USA cc Hosp 55 49 (10/20e73) 84 Knee M Y
Imamura et al. (2008)22 Brazil cc Unknown 84 71 (7) 100 Knee M Y Y Y
Keefe et al. (1997)69 USA co Hosp 40 62 (19) 53 Knee T Y
Kosek and Ordeberg (2000)24 Sweden cc Unknown 28 52 (29e67) 64 Hip M, T Y Y
Krause et al. (1995)46 Germany cc Unknown 100 53 58 Knee E, T Y
Appendix 3. (continued)
Author & year Country Design Setting Participants Age mean
(SD/range)
Female% Affected
joint
QST
modalities
QST
affected
Distal Remote Other*
Kulkarni et al. (2007)30 UK co Unknown 12 59 (52e67) 50 Knee T Y
Lee et al. (2011)23 USA cc Comm 59 58 (9) 73 Knee M, T Y
Lundblad et al. (2008)56 Sweden co Hosp 69 68 (40e80) 51 Knee E Y
Martinez et al. (2007)34 USA co Hosp 20 69 (9) 95 Knee M, T Y Y
Moss et al. (2007)37 Australia co Comm 38 65 (11/40e87) 66 Knee M Y
O’Driscoll and Jayson
(1974, 1975)25,26
UK cc Unknown 55 68 73 Hip M Y
Oliveira et al. (2009)70 Portugal cc Unknown 86 55 (10) 78 Not speciﬁed M Y
Parks et al. (2011)31 USA cc Unknown 23 52 (8) 30 Knee M Y
Sayed-Noor et al. (2008)71 Sweden cc Hosp 36 65 (45e82) 83 Hip M Y Y Y
Schmidt et al. (2010)72 Germany tri Hosp 30 (44e68) 73 Hand/hip/knee M Y
Shakoor et al. (2008)50 USA cc Hosp 41 52 (13) 76 Knee M Y Y
Shakoor et al. (2008)51 USA cc Comm 27 62 (10) 41 Hip M Y Y
Takeda and Wessel (1994)35 Canada RCT Unknown 40 62 (9) 50 Knee M Y
Wessel (1995)20 Canada cc Unknown 36 63 (8) 100 Knee M Y
Wilder-Smith et al. (2001)36 South Africa RCT Hosp 87 59 (55e65) 32 Hip/knee E Y
Williams et al. (2004)73 USA co Comm 154 66 (9) 66 Knee M Y
Wylde et al. (2011)38 UK cc Hosp 157 69 49 Knee M, T Y Y
Wylde et al. (2011)21 UK cc Hosp 100 70 (8) 44 Knee M, T Y Y
Study design: cc¼ case control, co¼ cases only, tri¼ uncontrolled trial.
Setting: Comm¼ community-based, Hosp¼ hospital-based.
QST modalities: C¼ Chemical, E¼ Electrical, M¼mechanical, T¼ Thermal.
* Other for QST test sites includes averaged (e.g., both sides of the body) and non-speciﬁed sites.
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